Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. METHODS: In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes. Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks. The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point). RESULTS: A total of 272 participants underwent randomization. At baseline, the mean body weight was 108.7 kg, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 37.9. At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group. At week 36, the mean change ranged from -9.4% to -14.7% with orforglipron and was -2.3% with placebo. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo. The use of orforglipron led to improvement in all prespecified weight-related and cardiometabolic measures. The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts. The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class. CONCLUSIONS: Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“Between 65% and 96% of participants taking orforglipron achieved an A1C level below 7.0% at 26 weeks.174”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [174]
In the citing paper
“In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to −14.7% compared to −2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [25]
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“In a multicenter phase 2 trial, 272 participants (mean age, 54.2 years; mean BMI, 37.9 kg/m 2 ) were randomly assigned to 1 of 4 doses of oral orforglipron (12, 24, 36, or 45 mg) once daily or placebo, for 36 weeks (Wharton et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Self-citationDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Self-citationLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Cited by
Items 201–300 of 509
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Next Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists?
Abel, E. D. (2023) · New England Journal of Medicine · doi:10.1056/nejme2307285 · Cited by 9
McIntyre, R. S. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241087 · Cited by 12
Morissette, A., & Mulvihill, E. E. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13065 · Cited by 8
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
Emerging Pharmacological Approaches for the Treatment of Arterial Hypertension
Schinzari, F., Montenero, R., Cardillo, C., & Tesauro, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040790 · Cited by 9
“In addition to weight reduction, treatment with orfoglipon was associated with an impressive decrease in systolic BP ( − 10.1 mmHg at the highest dose), considerably higher than that observed with the placebo ( − 1.8 mmHg) [62].”
InfluentialAlluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Alqatari, S. G., Alwaheed, A., Hasan, M. A., Argan, R. A., Alabdullah, M. M., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61071292 · Cited by 11
“Given the robust weight reduction observed—approaching 15%—Phase 3 trials are currently underway to further evaluate its efficacy and long-term safety [25].”
InfluentialMadhu, S. V., Kapoor, N., Das, S., Raizada, N., & Kalra, S. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_680_25 · Cited by 18
Updates on Anti-Obesity Medications in Children and Adolescents
Salama, M., Hassan, D., & Kumar, S. (2025) · Children · doi:10.3390/children12101390 · Cited by 10
“…also indicated that orforglipron, an oral, non-peptide GLP-1 receptor agonist, is associated with weight loss and improvement in cardiometabolic parameters in adults with obesity or in those with overweight status and at least one weight-related comorbidity, in the absence of diabetes [100,101].”
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“This represents a meaningful advance in obesity pharmacotherapy, potentially improving patient adherence and expanding access to GLP-1RA therapy for those who prefer oral medications or cannot tolerate injections [41] .”
InfluentialJordan, G., Young, S., & Alemán, J. O. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.006 · Cited by 12
Medical Management of Obesity: Current Trends and Future Perspectives
Calderón, A., Aguilera-Astudillo, M., Rojas, A. P., Dowlatshahi, S., Kansara, A., Shakil, J., & Patham, B. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1503 · Cited by 8
Chen, Z. J., Sun, Z., Zhang, Z., Lei, C., Ren, Z., Di, Y., & Wang, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1498927 · Cited by 9
“Past evidence indicates that the hypoglycemic regimen of GLP - 1RA may cause weight loss (45), and weight loss is associated with an increased risk of death for patients with lung cancer (46).”
Won, H., Cho, J., & Lee, S. (2025) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2025.33.e3 · Cited by 8
“[11], positioning orforglipron as a promising oral GLP-1 receptor agonist for both glycemic control and weight management.”
New Frontiers in Nutritional and Therapeutic Interventions for Obesity Phenotypes
Patti, A. M., Giglio, R. V., Ciaccio, M., Stoian, A. P., Salmen, T., Bica, I.-C., Rangraze, I. R., El‐Tanani, M., Rizzo, M., & Rizvi, A. A. (2025) · Medicina · doi:10.3390/medicina61040664 · Cited by 9
“For weight loss in overweight or obese patients, drugs such as GLP-1RAs with proven cardiovascular effects are preferred [51,52].”
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
Morse, B. L., Bhattachar, S., Ma, X., Coutant, D. E., Czeskis, B., Nicoll, C., & Cassidy, K. C. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1594 · Cited by 7
“5,6,12 The majority of TEAEs were gastrointestinal, assessed as treat-ment related by study investigators, of mild severity and resolved without treatment, except 1 TEAE of mild headache requiring paracetamol.”
Self-citationPieralice, S., Amendolara, R., Berna, V., Manganaro, G., Zurru, A., D’Onofrio, L., Risi, R., Alfonsi, M., Maddaloni, E., & Buzzetti, R. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s528569 · Cited by 10
Weight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach
Șeremet, O. C., Pușcașu, C., Andrei, C., Nițulescu, G., Zbârcea, C. E., & Olaru, O. T. (2025) · Medicina · doi:10.3390/medicina61111902 · Cited by 12
“By the end of the study, 46% to 75% of participants receiving orforglipron achieved a weight reduction of at least 10%, compared with 9% in the placebo group, accompanied by improvements in cardiometabolic risk markers [86].”
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
“Orforglipron, the first small molecule GLP-1 agonist, was developed by Eli Lilly reduced A1C by up to 1.5 % reduction and body weight by 16 lbs [144].”
InfluentialAdvances in Drug Treatments for Companion Animal Obesity
Zomer, H. D., & Cooke, P. S. (2024) · Biology · doi:10.3390/biology13050335 · Cited by 10
“Initial Phase 1 and 2 clinical trials indicate that orally active forms of these types of drugs produce weight loss in humans comparable to that obtained with injected tirzepatide and semaglutide [69,70], suggesting they can be effectively administered orally.”
ResultTrending Modalities in Type 2 Diabetes Prevention
Lundgrin, E. L., & Hatipoğlu, B. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf040 · Cited by 8
Alturki, M. S., Alkhodier, R. A., Gomaa, M. S., Hussein, D. A., Tawfeeq, N., Khzem, A. H. A., Pottoo, F. H., Albugami, S. A., Aldawsari, M. F., & Rants’o, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136131 · Cited by 7
A new era in obesity management
Stanford, F. C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00887-9 · Cited by 7
Advancements in the management of obesity: a review of current evidence and emerging therapies
Abdalla, M. A., Ssemmondo, E., Mark‐Wagstaff, C., & Sathyapalan, T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347258 · Cited by 10
“By the end of the study, the mean changes in body weight from baseline ranged from −8.6% to 12.6% across orforglipron doses compared to only −2% in the placebo group [78].”
BackgroundInfluentialTratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos
Pérez, J. S., & Miguel, G. A. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103074 · Cited by 8
Smith, G. D., Hofman, A., & Brennan, P. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-01090-5 · Cited by 9
“However, beyond the overall effect of obesity—and until recently intervention on this has been disappointing [43] - the epidemiological investigation of nutrition has been underwhelm-ing, with little consistent evidence to show for the considerable investment in this domain.”
Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus
Chatterjee, R., Galave, V. S. B., & Jindal, A. B. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01965-y · Cited by 7
“The development of small-molecule oral GLP-1 agonists such as orforglipron, may represent a paradigm shift by eliminating the need for injections entirely [167].”
InfluentialCrispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
“GLP-1RAs demonstrated an important positive effect on obesity by decreasing the appetite and delaying gastric emptying, thereby leading to an improvement in energy balance [57].”
Innovative Glucagon-based Therapies for Obesity
Belay, K. E., Jemal, R. H., & Tuyizere, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae197 · Cited by 8
Himmerich, H. (2025) · Der Nervenarzt · doi:10.1007/s00115-025-01813-x · Cited by 9
The management of hypothalamic obesity in craniopharyngioma
Dimitri, P. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102018 · Cited by 6
Zheng, J., Gaspar, R. C., Sakuma, I., Hubbard, B. T., Zhang, D., Nasiri, A. R., Kahn, M., Perelis, M., Samuel, V. T., Petersen, K. F., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06539-8 · Cited by 7
“Its prevalence continues to increase in tandem with the growing incidence of obesity and type 2 diabetes; however, there are few therapeutic options [2, 3].”
Tanashat, M., Al‐Ajlouni, Y. A., Abuelazm, M., Altobaishat, O., Manasrah, A., Turkmani, M. M., Khan, U., & Abouzid, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00726-z · Cited by 9
Ohwaki, K., Nakamura, C., Nasu, R., Takenouchi, K., & Hirase, T. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70157 · Cited by 5
Bhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., et al. (2025) · Medicine · doi:10.1097/md.0000000000046671 · Cited by 5
“Wharton et al [13] Canada”
Yuliantie, E., Trinh, P. N. H., Hick, C. A., Ebenhoch, R., Nar, H., Weichert, D., Christopoulos, A., Sexton, P. M., & Wootten, D. L. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116483 · Cited by 5
Obesity Management in South Asian Context
Das, S., Chappalagavi, A. S., Choudhury, A. K., Meher, D., Sahoo, D., Sahu, S. K., & Gupta, S. (2025) · Apollo Medicine · doi:10.1177/09760016251325966 · Cited by 5
“…with 2.4 mg; −13.2% with 3.6 mg and −14.9% with 4.8 mg dose Orforglipron Nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist Phase II [39] At week 36, the estimated mean change from baseline in body weight was −9.4% with the 12-mg, −12.5% with 24-mg, −13.5% with 36-mg and −14.7% with…”
InfluentialKim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Ellberg, C. C., Schwartz, H. R., Witt, A., McCowen, K. C., Fuentes, A. L., & Malhotra, A. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-025-00384-1 · Cited by 6
“…non-randomised For the researchers, a number of questions remain as well: a) Can oral agents such as orforglipron (a novel non-peptide GLP1-RA, not yet FDA approved) be used to maintain weight loss following tirzepatide induced weight loss [59],? Ongoing studies are addressing this question.”
Tantoush, M., Almaghrabi, Y., Abusbaeh, A., Ahmed, N., Tantush, A., Hamida, B. B., Sagher, M., Sager, M., Abouslima, A., Elbahnasawy, S. E., et al. (2026) · Cureus · doi:10.7759/cureus.102018 · Cited by 7
“References: [11,16,25-28] HbA1c: Glycated hemoglobin (hemoglobin A1c); kg/m²: Kilograms per square meter (unit of BMI); GLP-1: Glucagon-like peptide-1; T2D: Type 2 diabetes; USA: United States of America; NCT: ClinicalTrials.gov identifier prefix; mg: Milligrams; HOMA-B: Homeostatic model…”
InfluentialAlper, A., Peleg, G., Fagin, A., Shah, P. P., Chowdhury, I. Z., Gonzales, A., & FAILLACE, R. T. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00270-4 · Cited by 7
“This meta-analysis consists of four trials in obesity or T2D patients shows that oral Orforglipron, a non-peptide GLP-1RA, delivers consistent, clinically meaningful weight loss and glycemic improvements [23–25”
InfluentialAhmed, I. S., Tapponi, S. L., Manaa, H. M., Soltani, A., Hussein, E. S., Parvaresh, F. A., & Hussain, Z. (2026) · Journal of Obesity · doi:10.1155/jobe/6556057 · Cited by 5
Wang, Y., Zheng, J., Long, Y., Wu, W., & Zhu, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115989 · Cited by 5
Holst, J. J. (2024) · The Journal of Physiology · doi:10.1113/jp287461 · Cited by 5
“At any rate, therapies of these diseases should now include some form of GLP-1 receptor agonism, and future developments, which will probably bring not only new effective combination therapies, but also small molecule agonists of the receptors (Wharton et al., 2023), are awaited with excitement.”
Wang, S., Schwartz, P. F., & Mancuso, J. P. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02494-5 · Cited by 5
“In obesity trials, sometimes the dropout rate in some active group can be higher than the placebo group due to more aggressive titration scheme [47].”
Steinacher, E., Hammer, A., Baumer, U., Hofer, F., Kazem, N., Lenz, M. W., Leutner, M., Lang, I. M., Hengstenberg, C., Sulzgruber, P., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf023 · Cited by 5
López, G. P. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107122 · Cited by 5
Yang, Q., Starkey, D. R., Yang, J., Vaid, R. K., Kao, P.-K., Held, C. B., Argentine, M. D., Berglund, D., Brewer, A. C., Buser, J. Y., et al. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00185 · Cited by 6
EndoBridge 2023: highlights and pearls
Yıldız, B. O., Boguszewski, C. L., Boguszewski, M. C. D. S., Busetto, L., Celik, O., Fuleihan, G. E., Goulis, D. G., Hammer, G. D., Haymart, M. R., Kaltsas, G., et al. (2024) · HORMONES · doi:10.1007/s42000-024-00549-8 · Cited by 5
“Looking ahead, there are promising gut hormone therapies in Phase 2/Phase 3 clinical trials, including oral GLP-1 therapies such as semaglutide (25 mg and 50 mg) and the oral non-peptide GLP-1 agonist orforglipron [45].”
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Pourkarim, F., & Entezari‐Maleki, T. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2311840 · Cited by 5
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
“…the efficacy of both oral semaglutide and orforglipron for weight loss, it also appears that the total weight loss is less than what can be obtained with injectable molecules, 129,137 such as semaglutide 6 and tirzepatide, 138 and they still report gastrointestinal AEs as the main complication.”
Obesity and Comorbidity Management in Psoriatic Arthritis
Maharaj, A. B., Eder, L., & Ogdie, A. (2025) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2025.07.001 · Cited by 4
EndoCompass project: research roadmap for diabetes, obesity, and metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf065 · Cited by 5
Raza, S. S., Zakir, Z., Hashmat, A., Awan, S. K., & Varrassi, G. (2025) · Cureus · doi:10.7759/cureus.96739 · Cited by 8
Hammad, N., Ramadan, A. M., Nazmy, A., Elazab, A., & Abdelaziz, A. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261420404 · Cited by 4
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Qiu, L., Liu, J., & Hu, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870649 · Cited by 4
“Sixth, newer multi-agonists have impressive metabolic ef fi cacy but limited completed CVOT evidence (24, 25, 52, 53).”
InfluentialInnovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine
Romantsova, T. I. (2024) · Obesity and metabolism · doi:10.14341/omet13184 · Cited by 5
Ni, M., Chen, Y., Gu, W., Zhang, Y., Xu, M., Gu, Y., Chen, Y., Zhu, Y., Wang, X. D., Luo, Y., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70090 · Cited by 4
“In particular, GLP-1 receptor agonists (GLP-1RAs) have garnered considerable attention due to additional benefits like weight loss and cardiovascular protection [9–11].”
Self-citationThe history of the pharmacotherapy of obesity
Berkovskaya, M. A., Gurova, O. Y., Surkova, E. V., & Fadeev, V. V. (2025) · Problems of Endocrinology · doi:10.14341/probl13469 · Cited by 5
“Снижение массы тела как минимум на 10% к 36-й неделе произошло у 46–75% участников, получавших орфоргли-прон, по сравнению с 9%, получавших плацебо [56].”
Oral GLP-1 Receptor Agonists for Weight Loss
Krinsky, D., Marcucci, A., Mullally, J. A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000833 · Cited by 4
Yang, Q., Starkey, D. R., Vaid, R. K., Ortiz-Medina, X., Held, C. B., Argentine, M. D., Berglund, D., Hess, M., Brewer, A. C., Mathews, K. L., et al. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00184 · Cited by 5
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3
Zhou, J., Wang, F., & Li, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1646956 · Cited by 3
Wong, N. D., Karthikeyan, H., & Fan, W. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07583-z · Cited by 3
“Finally, early studies of the oral non-peptide GLP-1 receptor agonist orforglipron [20], as well as newer triple hormone agonists such as retatrutide [21], are showing benefits of significant weight loss efficacy.”
Jamal, A., Khan, S., Qadri, M., Shah, A., Iftikhar, H., Fatima, E., Ahmad, M., Sikandar, M., Jawed, I., Muneeb, M., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02635-8 · Cited by 3
Maanaoui, M., Debillon, F., Lenain, R., Defrance, F., Vantyghem, M., Triempont, M. V., Provôt, F., Chetboun, M., Kerr-Conte, J. A., Hamroun, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-83817-2 · Cited by 3
Auswirkungen „neuer“ Antidiabetika auf das Anästhesiemanagement
Rupprecht, B., & Dumps, C. (2025) · Die Anaesthesiologie · doi:10.1007/s00101-025-01521-w · Cited by 3
"Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024)
Tolkacheva, E. V., Saliev, A. Y., Salakhov, T. L., Balakin, K. V., Ivanov, R. A., & Chernyshov, V. V. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673366258250710101146 · Cited by 3
Orforglipron in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2594493 · Cited by 4
“Absolute weight loss ranged from 6.9 to 11.2 kg at week 26 and from 7.4 and 13.0 kg at week 36 [24].”
InfluentialSignificance of neuroendocrine systems and the gut-brain axis (GBA) in the regulation of obesity
Zhao, H., Li, Y., Cheng, R., Wang, Y., Ma, L., & Chen, W. (2026) · PeerJ · doi:10.7717/peerj.20400 · Cited by 5
Update on antiobesity pharmacotherapy in adults: Current and emerging options
Ziyadeh, F., Saliba, S., Bacha, D. S., Mauer, Y., Griebeler, M. L., & Burguera, B. G. (2026) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.93a.24112 · Cited by 3
Incretin therapy and obesity: current and future pharmacologic possibilities
Moss, E., Hawk, K., Lollis, K., & Clements, J. N. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0151 · Cited by 3
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Kim, B. R. (2026) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70227 · Cited by 4
“Furthermore, oral GLP-1 RAs, such as orfor-glipron and danuglipron, are currently demonstrating comparable efficacy in weight loss to their injectable counterparts, representing promising alternatives for the future [81].”
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Abdallfatah, A., Reyad, M., El‐Nemr, A. F., Maihoub, O., Elsekhary, A., Eladawi, S., Ayalew, B. D., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70222 · Cited by 3
“Overall, four RCTs were rated as having a low risk of bias [13, 15, 15, 31], while one RCT was rated as having some concerns [17] (Figure 2).”
Patient preferences for pharmacological treatments for obesity: The VOICE study
Houle, C. R., Gelhorn, H. L., Cutts, K. N., Samuelson, A., & Xavier, N. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100278 · Cited by 3
“Each have demonstrated > 10% average weight reduction from baseline in clinical trials [26,27].”
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?
Tan, T. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00157-3 · Cited by 3
Je, I., Kim, T.-K., Lee, M. Y., Lee, M.-Y., An, K., Park, J.-T., & Kim, K.-Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178143 · Cited by 3
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
Zhu, J., & Wilding, J. P. H. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01181-4 · Cited by 4
“Moreover, orforglipron (doses escalating from 2 to 40 mg qd po) was associated with a significant 12.6% and 14.7% of body weight reduction from baseline (BMI = 37.8 kg/m 2 ) at week 26 and week 36 in patients with overweight or obesity [104].”
InfluentialExploring the Molecular Pathology of Iatrogenic Amyloidosis
Bonilauri, B. (2024) · Journal of Molecular Pathology · doi:10.3390/jmp5020016 · Cited by 4
“Therefore, with the significant increase in the use of GLP-1-receptor agonist drugs (GLP-1Ra), these cases should be closely studied, although more advanced drugs that only require weekly applications and/or are administered orally are entering the market [70–72].”
BackgroundA Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease
AlHabeeb, W., Kinsara, A. J., Bakhsh, A., Tash, A. A., Alshammary, A., Almasood, A. S., Alghalayini, K. W., Arafah, M., Hamdy, O., Alsifri, S. N., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1391 · Cited by 6
“Moreover, orforglipron led to improvement in all prespeci fi ed weight-related and cardiometabolic measures [336].”
BackgroundFuture Medications for Obesity and Clinical Implications
Garvey, W. T. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0004 · Cited by 3
Prise en charge pharmacologique de l’obésité : l’apport des nouvelles classes médicamenteuses
Bauduceau, B., Bordier, L., Schlienger, J.-L., & Monnier, L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.008 · Cited by 3
Yang, Q., Brewer, A. C., Ryan, S. J., Starkey, D. R., Vaid, R. K., Huang, P. C., Jia, M., Liu, P., Liang, L., Meng, L., et al. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00183 · Cited by 3
Bays, H. E., Brown, C., & Fitch, A. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100079 · Cited by 3
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
(2025) · New England Journal of Medicine · doi:10.1056/nejmc2515117 · Cited by 2
Self-citationHIV Treatment and Obesity: What’s New?
Freitas, P., & Ribeiro, S. (2024) · Infectious diseases · doi:10.5772/intechopen.112667 · Cited by 2
Qi, W., Boca, S. M., Boianelli, A., Fredberg, M., Lundqvist, S., Davies, G., Field, J., Brighton, C. A., Snijder, A., Grundevik, P., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103683 · Cited by 3
Zhou, L., Duanmu, W., Tan, F., Gu, X., Che, H., & Yin, W. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-13377-2 · Cited by 2
“This enables GLP-1RA to exert multisystem effects beyond glycemic control, providing additional benefits such as weight reduction, blood pressure regulation, lipid profile improvement, and hepatorenal protection in T2DM management [26– 28].”
Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 3
“GLP-1 receptor agonists (GLP-1Ra) are incretin-based treatments currently being used for lowering HbA1c and weight management [108–111].”
Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687601 · Cited by 3
Kanu, C., Kimel, M., Clucas, C., GOETZ, I. A., Neff, L. M., Boye, K. S., & Karn, H. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03460-9 · Cited by 3
“…insulinotropic polypeptide receptor agonist), and retatrutide (investigational glucagon-like peptide-1, glucose-dependent insu-linotropic polypeptide, and glucagon receptor agonist) affect the regulation of body-fat mass and energy homeostasis and can promote substantial weight reduction [7–16].”
Liu, J., Chen, Z., Yang, Q., Lin, H., Wang, S., Li, M., Wang, T., Zhao, Z., Xu, M., Chen, Y., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01379-y · Cited by 2
“4, Supplementary Data 7).”
Lv, J., Zhang, S., Qu, Y., Cao, Y., Zhang, J., Dai, X., & Shi, L. S. (2026) · Health and Metabolism · doi:10.53941/hm.2026.100005 · Cited by 3
“A Phase II multicenter RCT (n = 272, average age, 54.2 years; average BMI, 37.9 kg/m 2 ) evaluated the weight loss efficacy of orforglipron administration at different doses (12, 24, 36, or 45 mg) versus a placebo for a duration of 36 weeks [27].”
Influential
Metadata
- Authors
- Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., & Konig, M.
- Affiliations
- Eli Lilly (United States) (US)
- From McMaster University, York University, and Wharton Weight Management Clinic — all in Toronto (S.W.); Texas Diabetes and Endocrinology, Austin (T.B.), and Velocity Clinical Research at Medical City, Dallas (J.R.) — both in Texas; Alliance for Multispecialty Research, Norman, OK (L.C.); and Eli Lilly, Indianapolis (S.R., R.L., X.M., K.J.M., A.H., D.R., E.P., C.K., M.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-07
- Volume
- 389
- Issue
- 10
- Pages
- 877-888
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4381716537
- Semantic Scholar
- db8284957df7f480bc8b5957f73388bfd42590cf
- Cited by
- 478
- References
- 19
- Citations by year
- 2026: 125 · 2025: 175 · 2024: 133 · 2023: 45
- FWCI
- 74.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- orforglipron, GLP-1 receptor agonists, obesity, weight loss, cardiometabolic risk, gastrointestinal adverse effects, dose escalation, overweight adults, weight change, drug safety and efficacy, weight-related comorbidities, dose-response relationship, dose-limiting adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.